(firstQuint)A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.

5 mg - for the Treatment of Insomnia.

 The primary objective of the study is to determine whether eszopiclone (Eurofarma) is non-inferior to the reference drug zopiclone (Imovane(R), Sanofi-Aventis) in the treatment of insomnia.

 To that end, the latency to persistent sleep (LPS) will be used as a primary endpoint at the end of the treatment, measured by polysomnography.

 The secondary objectives and endpoints of this study are as follows: - To evaluate the efficiency of eszopiclone compared to zopiclone by means of the patient's clinical history, using as secondary endpoints: - Variables of the sleep diary of the Associacao Fundo de Incentivo a Psicofarmacologia (see Appendix A), namely: - Latency time to the beginning of the sleep; - Frequency of night wake-ups; - Time awake during bedtime; - Early morning awakening; - Total time in bed; - Sleep efficiency; - Sleep variables measured by actigraph; - Insomnia Severity Index (see Appendix B);45 - Pittsburgh Sleep Quality Index (see Appendix C);46 - To evaluate the safety of eszopiclone compared to zopiclone by means of adverse events in each study arm.

.

 A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.

5 mg - for the Treatment of Insomnia@highlight

The primary objective of the study is to determine whether eszopiclone (Eurofarma) is non-inferior to the reference drug zopiclone (Imovane(R), Sanofi-Aventis) in the treatment of insomnia.

